HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• Electronic symptom-reporting tools break down care barriers, but practical challenges remain
• Nivolumab-ipilimumab a new standard of care for renal cell carcinoma Manuela Schmidinger, MD
• ASH to honor several hematology leaders
• FDA approves Lynparza for ovarian cancer maintenance therapy
• UT Southwestern names cancer center director
• Aestas horribilis: Taking tragedy for granted Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
• FDA approves Besponsa for acute lymphoblastic leukemia
• FDA approves Imbruvica as first therapy for chronic graft-versus-host disease
• FDA approves Mvasi, first biosimilar for cancer
• FDA approves Vyxeos for poor-prognosis acute myeloid leukemia
• FDA grants breakthrough therapy designation to several oncology agents
• FDA grants priority review to six hematology/oncology agents
• FDA grants regulatory clearance to QuantX for breast cancer diagnosis
• Dabigatran associated with higher 30-day readmission rate for bleeding than warfarin
• Guidelines address ‘unmet need’ for grading, management of CAR T-cell toxicities
• Hypofractionated radiotherapy may improve glottic cancer survival
• Lenalidomide extends myeloma survival after stem cell transplantation
• Patient-reported outcomes rarely used as endpoints in studies of elderly patients with cancer
• Survival rates after cardiac arrest lower in patients with cancer
• Tumor marker associated with poor ovarian cancer outcomes
• Vorinostat may prevent graft-versus-host disease after unrelated donor bone marrow transplant
• Abemaciclib plus endocrine therapy improves outcomes for certain women with advanced breast cancer
• Addition of radiation therapy to chemotherapy extends PFS in advanced non-small cell lung cancer
• Adjuvant imatinib beneficial for high-risk gastrointestinal stromal tumors
• Adjuvant vemurafenib confers clinical benefit in resected BRAF V600-positive melanoma
• Dabrafenib plus trametinib shows promise over docetaxel for BRAF-mutated NSCLC
• Dabrafenib-trametinib combination doubles RFS in resected stage III melanoma
• Durvalumab extends PFS in stage III lung cancer
• Efficacy of high-dose brachytherapy for cervical cancer differs by dose
• Ipilimumab with radiation may slow late-stage cancer tumor growth
• iRECIST accurately detects pseudo-progression in lung cancer
• Liver cancer risk factors more prevalent among Mexicans living in US
• Nearly a quarter of women with small breast cancers at risk for distant metastases
• Nivolumab plus ipilimumab outperforms sunitinib in certain kidney cancers
• Patient education may narrow racial disparity gap in lung cancer care
• Pelvic radiation remains standard treatment for early-stage endometrial cancer
• Religiously tailored education increases mammography use in Muslim women
• Reproductive potential can be maintained after ovarian tissue transplant
• Survey shows variability in thoracic radiotherapy dosing, fractionation
• Tocilizumab manages adverse events following PD-1 blockade therapy
• Undiagnosed depression common among patients with cancer
• Are patient-reported outcomes data sufficient to safely reduce face-to-face oncology visits?